HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ira Pastan Selected Research

Edema (Dropsy)

1/2019Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner.
5/2012Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
9/2005Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
4/2005Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ira Pastan Research Topics

Disease

184Neoplasms (Cancer)
04/2024 - 03/2001
41Mesothelioma
11/2022 - 06/2002
35Hairy Cell Leukemia
11/2021 - 02/2002
20Pancreatic Neoplasms (Pancreatic Cancer)
01/2024 - 05/2005
16Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 05/2002
15Prostatic Neoplasms (Prostate Cancer)
12/2018 - 03/2002
15Leukemia
10/2018 - 04/2002
14Adenocarcinoma
01/2024 - 08/2003
14Breast Neoplasms (Breast Cancer)
01/2022 - 05/2002
13Malignant Mesothelioma
03/2020 - 06/2004
12B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
04/2014 - 02/2002
11Neoplasm Metastasis (Metastasis)
01/2023 - 02/2002
11Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2020 - 03/2010
10Hematologic Neoplasms (Hematological Malignancy)
01/2020 - 10/2006
9Lung Neoplasms (Lung Cancer)
01/2023 - 06/2002
8Adenocarcinoma of Lung
01/2020 - 06/2002
8Glioblastoma (Glioblastoma Multiforme)
01/2016 - 05/2002
8Glioma (Gliomas)
01/2016 - 01/2005
7Carcinoma (Carcinomatosis)
01/2024 - 10/2006
7Proteinuria
01/2019 - 04/2005
7Lymphoma (Lymphomas)
04/2013 - 07/2002
6Capillary Leak Syndrome
01/2023 - 01/2013
6Hemolytic-Uremic Syndrome
10/2017 - 09/2005
6Testicular Neoplasms (Testicular Cancer)
01/2012 - 03/2002
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2023 - 06/2002
4Fibrosis (Cirrhosis)
01/2021 - 01/2016
4Residual Neoplasm
01/2020 - 05/2006
4Edema (Dropsy)
01/2019 - 04/2005
4Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
05/2017 - 01/2010
4Stomach Neoplasms (Stomach Cancer)
04/2016 - 02/2002
4Disease Progression
12/2014 - 06/2010
4Non-Hodgkin Lymphoma (Lymphosarcoma)
02/2014 - 10/2006
4B-Cell Lymphoma (Lymphoma, B Cell)
05/2012 - 11/2006
4Brain Neoplasms (Brain Tumor)
01/2012 - 10/2003
3Ureteral Obstruction
11/2022 - 03/2011
3Inflammation (Inflammations)
01/2022 - 01/2019
3Colorectal Neoplasms (Colorectal Cancer)
03/2020 - 12/2007
3Hepatocellular Carcinoma (Hepatoma)
01/2020 - 05/2008
3Hypersensitivity (Allergy)
01/2019 - 12/2014
3Thrombotic Microangiopathies
10/2017 - 09/2014
3Hypoalbuminemia
10/2017 - 09/2005
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2017 - 09/2007

Drug/Important Bio-Agent (IBA)

140Immunotoxins (Immunotoxin)IBA
01/2024 - 02/2002
85MesothelinIBA
04/2024 - 06/2002
64Proteins (Proteins, Gene)FDA Link
01/2022 - 02/2002
39AntigensIBA
01/2023 - 03/2001
33ExotoxinsIBA
01/2024 - 04/2002
29Monoclonal AntibodiesIBA
03/2020 - 03/2001
21AntibodiesIBA
01/2024 - 04/2002
18LMB-100IBA
01/2024 - 08/2014
18immunotoxin HA22IBA
11/2021 - 11/2006
13Membrane Proteins (Integral Membrane Proteins)IBA
04/2024 - 02/2003
12Differentiation AntigensIBA
01/2021 - 06/2004
11EpitopesIBA
04/2024 - 04/2004
11Messenger RNA (mRNA)IBA
01/2016 - 03/2002
10Surface Antigens (Surface Antigen)IBA
11/2020 - 04/2004
10Peptides (Polypeptides)IBA
12/2018 - 04/2004
9amatuximabIBA
12/2016 - 12/2007
8Membrane Glycoproteins (Membrane Glycoprotein)IBA
01/2019 - 11/2002
7VaccinesIBA
12/2018 - 04/2004
7SS1(dsFv)PE38IBA
11/2018 - 11/2002
7B3(Fv)-PE38KDEL recombinant immunotoxinIBA
01/2018 - 02/2002
7Paclitaxel (Taxol)FDA LinkGeneric
05/2017 - 08/2006
7ErbB Receptors (EGF Receptor)IBA
01/2016 - 10/2004
7Immunoconjugates (Immunoconjugate)IBA
01/2016 - 12/2008
6purineIBA
01/2020 - 02/2005
6Biomarkers (Surrogate Marker)IBA
01/2020 - 04/2012
6TARPIBA
12/2018 - 08/2003
6Bacterial ToxinsIBA
01/2018 - 02/2010
6T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
01/2017 - 01/2008
6Neoplasm Antigens (Tumor Antigens)IBA
12/2016 - 04/2004
6Cytotoxins (Cytolysins)IBA
01/2013 - 07/2002
6RFB4(dsFv)-PE38 recombinant immunotoxinIBA
10/2011 - 01/2005
5Immunoglobulin Variable RegionIBA
04/2024 - 10/2006
5Pentostatin (Nipent)FDA LinkGeneric
01/2020 - 10/2009
5Neutralizing AntibodiesIBA
03/2016 - 08/2008
5epidermal growth factor receptor VIIIIBA
01/2016 - 05/2010
5Antineoplastic Agents (Antineoplastics)IBA
06/2014 - 01/2006
5HLA-A2 Antigen (HLA A2 Antigen)IBA
01/2013 - 04/2004
5Glycoproteins (Glycoprotein)IBA
07/2011 - 06/2002
4CytokinesIBA
01/2023 - 08/2007
4CollagenIBA
01/2021 - 11/2002
4CreatinineIBA
11/2020 - 05/2012
4Immune Checkpoint InhibitorsIBA
01/2020 - 12/2016
4Immunoglobulin FragmentsIBA
01/2020 - 01/2007
4CladribineFDA LinkGeneric
01/2020 - 05/2006
4Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2016 - 06/2011
4Immunoglobulin G (IgG)IBA
01/2016 - 05/2005
4Single-Chain AntibodiesIBA
01/2016 - 06/2002
4RNA (Ribonucleic Acid)IBA
05/2008 - 05/2002
3Chimeric Antigen ReceptorsIBA
04/2024 - 06/2015
3Peptide Hydrolases (Proteases)FDA Link
04/2024 - 04/2009
3AlbuminsIBA
01/2022 - 10/2018
3GlypicansIBA
01/2022 - 05/2017
3Rituximab (Mabthera)FDA Link
01/2020 - 07/2002
3Transaminases (Aminotransferases)IBA
10/2017 - 09/2005
3T-Cell Antigen Receptors (T-Cell Receptor)IBA
08/2016 - 04/2004

Therapy/Procedure

86Therapeutics
04/2024 - 03/2001
30Immunotherapy
04/2024 - 03/2002
17Drug Therapy (Chemotherapy)
01/2020 - 12/2007